3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
lutetium Lu 177 dotatate
29
Everolimus
19
Temozolomide
11
gallium Ga 68 dotatate
10
Nivolumab
10
Magnetic Resonance Spectroscopy
10
Capecitabine
9
pembrolizumab
8
lanreotide
8
Positron Emission Tomography Computed Tomography
8
cabozantinib
7
3-Iodobenzylguanidine
7
177Lu-octreotide, DOTA(0)-Tyr(3)-
7
Somatostatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
lenvatinib
5
Octreotide
5
Lutetium-177
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Carboplatin
5
avelumab
4
Positron-Emission Tomography
4
Ipilimumab
4
Bevacizumab
4
surufatinib
3
pasireotide
3
fluorodopa F 18
3
copper dotatate CU-64
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroendocrine Tumors
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled